Souza José Diogo S, Zuardi Antonio W, Guimarães Francisco S, Osório Flávia de Lima, Loureiro Sonia Regina, Campos Alline Cristina, Hallak Jaime E C, Dos Santos Rafael G, Machado Silveira Isabella Lara, Pereira-Lima Karina, Pacheco Julia Cozar, Ushirohira Juliana Mayumi, Ferreira Rafael Rinaldi, Costa Karla Cristinne Mancini, Scomparin Davi Silveira, Scarante Franciele Franco, Pires-Dos-Santos Isabela, Mechoulam Raphael, Kapczinski Flávio, Fonseca Benedito A L, Esposito Danillo L A, Andraus Maristela Haddad, Crippa José Alexandre S
Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
National Institute for Science and Technology-Translational Medicine, Ribeirão Preto, Brazil.
Front Pharmacol. 2022 Oct 3;13:856846. doi: 10.3389/fphar.2022.856846. eCollection 2022.
To assess whether the effects of oral administration of 300 mg of Cannabidiol (CBD) for 28 days on mental health are maintained for a period after the medication discontinuation. This is a 3-month follow-up observational and clinical trial study. The data were obtained from two studies performed simultaneously by the same team in the same period and region with Brazilian frontline healthcare workers during the COVID-19 pandemic. Scales to assess emotional symptoms were applied weekly, in the first month, and at weeks eight and 12. The primary outcome was that, compared to the control group, a significant reduction in General Anxiety Disorder-7 Questionnaire (GAD-7) from baseline values was observed in the CBD group on weeks two, four, and eight (Within-Subjects Contrasts, time-group interactions: F = 7.67; = 0.006; η = 0.06; F = 6.58; = 0.01; η = 0.05; F = 4.28; = 0.04; η = 0.03, respectively) after the end of the treatment. The anxiolytic effects of CBD in frontline health care professionals during the COVID-19 pandemic were maintained up to 1 month after the treatment discontinuation, suggesting a persistent decrease in anxiety in this group in the real world. Future double-blind placebo-controlled clinical trials are needed to confirm the present findings and weigh the benefits of CBD therapy against potential undesired or adverse effects.
评估口服300毫克大麻二酚（CBD）28天对心理健康的影响在停药后一段时间内是否持续存在。这是一项为期3个月的随访观察性临床试验研究。数据来自同一团队在同一时期和地区与巴西一线医护人员同时进行的两项研究，研究时间为新冠疫情期间。在第一个月以及第8周和第12周，每周应用评估情绪症状的量表。主要结果是，与对照组相比，在治疗结束后的第2周、第4周和第8周，CBD组的广泛性焦虑障碍-7问卷（GAD-7）较基线值显著降低（受试者内对比，时间-组交互作用：F = 7.67；P = 0.006；η² = 0.06；F = 6.58；P = 0.01；η² = 0.05；F = 4.28；P = 0.04；η² = 0.03）。在新冠疫情期间，CBD对一线医护人员的抗焦虑作用在停药后长达1个月内持续存在，这表明在现实世界中该组焦虑水平持续下降。未来需要进行双盲安慰剂对照临床试验以证实目前的研究结果，并权衡CBD治疗的益处与潜在的不良或有害影响。
